Plain-English translation of NCT07742215 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called BCD-248 paired with daratumumab to see if it can help people whose multiple myeloma has come back or stopped responding to previous treatments. Researchers want to compare this new combination against the current standard treatment (daratumumab, pomalidomide, and dexamethasone) to find out which works better and has fewer side effects.
Multiple myeloma often returns or becomes resistant to treatment, leaving patients with limited options. This medication aims to give people with relapsed or resistant myeloma a more effective choice that may work better than existing treatments.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the new medication combination (BCD-248 with daratumumab) or the current standard treatment (daratumumab, pomalidomide, and dexamethasone). You will visit the study center regularly for blood tests, imaging scans, and monitoring of side effects. The study follows you to see how well the treatment works and how safe it is over time.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
Belarus
Russia